Kurt Losert 
In the video below, Dr. Juliane Walz discusses a new clinical trial that is now open to patient enrollment at The University Hospital Tübingen in Tübingen, Germany. This FusionVAC22_02 clinical trial is designed to test the safety and efficacy of a peptide vaccine to delay or prevent the recurrence of fibrolamellar carcinoma (FLC). The peptide …
Cancers grow through uncontrolled cell proliferation. Repeated rounds of division of single cells to yield “daughter” cells cause tumors to expand exponentially. Cancer therapy aims not only to slow down or prevent cell division, but also to cause the malignant cells to die. Efficient killing is crucial because even a tumor that is barely detectable …
The U.S. Department of Defense has asked FCF to help to recruit community members to serve as consumer reviewers for the Peer Reviewed Cancer Research Program …
In a recent study funded by FCF, scientists at Fred Hutch Cancer Center in Seattle, Washington outlined the potential importance of Polo-like kinase 1 (PLK1) as a promising therapeutic target in FLC. The paper, DNAJ-PKAc fusion heightens PLK1 inhibitor sensitivity in fibrolamellar carcinoma, was published on April 24 in the journal Gut. The effort was …
FCF is pleased to announce its partnership with Dialectic Therapeutics to supply an experimental drug, DT2216, for a planned clinical trial for fibrolamellar patients. Under the agreement, FCF will fund the production of the DT2216 necessary to support the trial. The Foundation’s funding of the manufacturing costs of the drug was crucial to ensure the …
Congratulations to Dr. Juliane Walz of the University of Tübingen who was recently honored at überDACHt – Roche Science & Innovation Summit with the “Best Overall Award” for the upcoming fibrolamellar clinical trial, FusionVac_22_02. The event in Basel, Switzerland on March 21, 2025, brought together researchers from Germany, Austria and Switzerland to discuss innovations in …
FCF is pleased to announce that we have awarded Yasemin Sancak, PhD, of the University of Washington a grant to study the metabolic implications and targetability of mitochondrial calcium signaling in FLC. Dr. Sancak’s lab studies mitochondria, the “powerhouses of the cell” that produce most of a cell’s energy. Dysfunctional mitochondria are linked to various …
February 28th is Rare Disease Day — a worldwide event hoping to improve the lives of the 300 million people worldwide who are living with rare diseases, their families, and their caregivers. Rare Disease Day was launched in 2008 by EURORDIS – Rare Diseases Europe and takes place on the last day of February each year in more …
FCF is pleased to announce that it has awarded a grant to Praveen Sethupathy, PhD, of Cornell University to outline the “spatial transcriptomics” of FLC. Dr. Sethupathy’s lab has been a leader in functional genomic studies, especially for liver and gastro-intestinal cancers. They also have extensive experience in FLC research. His group has focused on …